Clinical Focus ›› 2022, Vol. 37 ›› Issue (3): 279-284.doi: 10.3969/j.issn.1004-583X.2022.03.016
Previous Articles Next Articles
-
Received:2022-02-09Online:2022-03-20Published:2022-04-02
CLC Number:
Cite this article
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.03.016
| [1] |
Warburg O, Wind F, Negelein E. The metabolism of tumors in the body[J]. J Gen Physiol, 1927, 8(6):519-530.
doi: 10.1085/jgp.8.6.519 pmid: 19872213 |
| [2] |
Lin Y, Lv F, Liu F, et al. High expression of pyruvate kinase m2 is associated with chemosensitivity to epirubicin and 5-fluorouracil in breast cancer[J]. J Cancer, 2015, 6(11):1130-1139.
doi: 10.7150/jca.12719 URL |
| [3] |
Shiroki T, Yokoyama M, Tanuma N, et al. Enhanced expression of the M2 isoform of pyruvate kinase is involved in gastric cancer development by regulating cancer-specific metabolism[J]. Cancer Sci, 2017, 108(5):931-940.
doi: 10.1111/cas.13211 URL |
| [4] |
Wang C, Jiang J, Ji J, et al. PKM2 promotes cell migration and inhibits autophagy by mediating PI3K/AKT activation and contributes to the malignant development of gastric cancer[J]. Sci Rep, 2017, 7(1):2886.
doi: 10.1038/s41598-017-03031-1 URL |
| [5] |
Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth[J]. Nature, 2008, 452(7184):230-233.
doi: 10.1038/nature06734 URL |
| [6] |
Zhang Z, Deng X, Liu Y, et al. PKM2, function and expression and regulation[J]. Cell Biosci, 2019, 9:52.
doi: 10.1186/s13578-019-0317-8 pmid: 31391918 |
| [7] |
Yuan C, Li Z, Wang Y, et al. Overexpression of metabolic markers PKM2 and LDH5 correlates with aggressive clinicopathological features and adverse patient prognosis in tongue cancer[J]. Histopathology, 2014, 65(5):595-605.
doi: 10.1111/his.2014.65.issue-5 URL |
| [8] |
Kurihara-Shimomura M, Sasahira T, Nakashima C, et al. The multifarious functions of pyruvate kinase M2 in oral cancer cells[J]. Int J Mol Sci, 2018, 19(10):2907.
doi: 10.3390/ijms19102907 URL |
| [9] |
Mukherjee J, Ohba S, See WL, et al. PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells[J]. Int J Cancer, 2016, 139(1):99-111.
doi: 10.1002/ijc.30041 pmid: 26874904 |
| [10] |
Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(13):2181-9210.
doi: 10.1200/JCO.2009.26.2543 URL |
| [11] |
Sun H, Zhu A, Zhang L, et al. Knockdown of PKM2 suppresses tumor growth and invasion in lung adenocarcinoma[J]. Int J Mol Sci, 2015, 16(10):24574-24587.
doi: 10.3390/ijms161024574 URL |
| [12] |
Guo CY, Zhu Q, Tou FF, et al. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma[J]. BMC Cancer, 2019, 19(1):289.
doi: 10.1186/s12885-019-5519-2 URL |
| [13] |
Meng MB, Wang HH, Guo WH, et al. Targeting pyruvate kinase M2 contributes to radiosensitivity of non-small cell lung cancer cells in vitro and in vivo[J]. Cancer Lett, 2015, 356(2 Pt B):985-993.
doi: 10.1016/j.canlet.2014.11.016 URL |
| [14] |
Shi HS, Li D, Zhang J, et al. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice[J]. Cancer Sci, 2010, 101(6):1447-1453.
doi: 10.1111/cas.2010.101.issue-6 URL |
| [15] |
Wang Y, Zhao H, Zhao P, et al. Targeting PKM2 promotes chemosensitivity of breast cancer cells in vitro and in vivo[J]. Cancer Biomark, 2021, 32(2):221-230.
doi: 10.3233/CBM-210111 URL |
| [16] | Fukuda S, Miyata H, Miyazaki Y, et al. Pyruvate kinase M2 modulates esophageal squamous cell carcinoma chemotherapy response by regulating the pentose phosphate pathway[J]. Ann Surg Oncol, 2015, 22(Suppl 3):S1461-1468. |
| [17] |
Jiang M, Wu Y, Qi L, et al. Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma[J]. Chem Biol Interact, 2021, 350:109704.
doi: 10.1016/j.cbi.2021.109704 URL |
| [18] | 马素珍, 曾震军, 潘晓丽, 等. 糖酵解关键酶在结直肠癌组织中的表达及其临床意义[J]. 肿瘤, 2017, 37(7): 723-731+741. |
| [19] |
Lu WQ, Hu YY, Lin XP, et al. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells[J]. Oncotarget, 2017, 8(27):44171-44185.
doi: 10.18632/oncotarget.v8i27 URL |
| [20] |
Li Q, Cao L, Tian Y, et al. Butyrate suppresses the proliferation of colorectal cancer cells via targeting pyruvate kinase M2 and metabolic reprogramming[J]. Mol Cell Proteomics, 2018, 17(8):1531-1545.
doi: 10.1074/mcp.RA118.000752 URL |
| [21] |
Yang P, Ding GB, Liu W, et al. Tannic acid directly targets pyruvate kinase isoenzyme M2 to attenuate colon cancer cell proliferation[J]. Food Funct, 2018, 9(11):5547-5559.
doi: 10.1039/C8FO01161C URL |
| [22] |
Li TE, Wang S, Shen XT, et al. PKM2 drives hepatocellular carcinoma progression by inducing immunosuppressive microenvironment[J]. Front Immunol, 2020, 11:589997.
doi: 10.3389/fimmu.2020.589997 URL |
| [23] |
Feng J, Wu L, Ji J, et al. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1):204.
doi: 10.1186/s13046-019-1194-z URL |
| [24] |
Feng J, Dai W, Mao Y, et al. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1alpha/PPAR-gamma/PKM2-mediated glycolysis[J]. J Exp Clin Cancer Res, 2020, 39(1):24.
doi: 10.1186/s13046-020-1528-x URL |
| [25] |
Lu W, Cao Y, Zhang Y, et al. Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer[J]. Sci Rep, 2016, 6:26351.
doi: 10.1038/srep26351 URL |
| [26] |
Hu H, Tu W, Chen Y, et al. The combination of PKM2 overexpression and M2 macrophages infiltration confers a poor prognosis for PDAC patients[J]. J Cancer, 2020, 11(8):2022-2031.
doi: 10.7150/jca.38981 URL |
| [27] |
James AD, Richardson DA, Oh IW, et al. Cutting off the fuel supply to calcium pumps in pancreatic cancer cells: Role of pyruvate kinase-M2 (PKM2)[J]. Br J Cancer, 2020, 122(2):266-278.
doi: 10.1038/s41416-019-0675-3 URL |
| [28] | Zhu Q, Hong B, Zhang L, et al. Pyruvate kinase M2 inhibits the progression of bladder cancer by targeting MAKP pathway[J]. J Cancer Res Ther, 2018, 14(Suppl):S616-S621. |
| [29] |
Huang C, Huang Z, Bai P, et al. Expression of pyruvate kinase M2 in human bladder cancer and its correlation with clinical parameters and prognosis[J]. Onco Targets Ther, 2018, 11:2075-2082.
doi: 10.2147/OTT URL |
| [30] |
Zhou H, Wang X, Mo L, et al. Role of isoenzyme M2 of pyruvate kinase in urothelial tumorigenesis[J]. Oncotarget, 2016, 7(17):23947-23960.
doi: 10.18632/oncotarget.v7i17 URL |
| [31] |
Wang Y, Hao F, Nan Y, et al. PKM2 inhibitor shikonin overcomes the cisplatin resistance in bladder cancer by inducing necroptosis[J]. Int J Biol Sci, 2018, 14(13):1883-1891.
doi: 10.7150/ijbs.27854 URL |
| [32] |
Wang X, Zhang F, Wu XR. Inhibition of pyruvate kinase M2 markedly reduces chemoresistance of advanced bladder cancer to cisplatin[J]. Sci Rep, 2017, 7:45983.
doi: 10.1038/srep45983 URL |
| [33] |
Dey P, Son JY, Kundu A, et al. Knockdown of pyruvate kinase m2 inhibits cell proliferation, metabolism, and migration in renal cell carcinoma[J]. Int J Mol Sci, 2019, 20(22) :5622.
doi: 10.3390/ijms20225622 URL |
| [34] |
Yang GJ, Wu J, Leung CH, et al. A review on the emerging roles of pyruvate kinase M2 in anti-leukemia therapy[J]. Int J Biol Macromol, 2021, 193(Pt B):1499-1506.
doi: 10.1016/j.ijbiomac.2021.10.213 URL |
| [35] |
Huang Y, Chen LM, Xie JY, et al. High expression of PKM2 was associated with the poor prognosis of acute leukemia[J]. Cancer Manag Res, 2021, 13:7851-7858.
doi: 10.2147/CMAR.S331076 URL |
| [36] |
Gao P, Shen S, Li X, et al. Dihydroartemisinin inhibits the proliferation of leukemia cells K562 by suppressing PKM2 and GLUT1 mediated aerobic glycolysis[J]. Drug Des Devel Ther, 2020, 14:2091-2100.
doi: 10.2147/DDDT.S248872 URL |
| [37] |
He Y, Wang Y, Liu H, et al. Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance[J]. Leuk Res, 2015, 39(12):1428-1436.
doi: 10.1016/j.leukres.2015.09.019 URL |
| [38] |
Najera L, Alonso-Juarranz M, Garrido M, et al. Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma[J]. Br J Dermatol, 2019, 181(1):114-127.
doi: 10.1111/bjd.2019.181.issue-1 URL |
| [39] |
Liu ZX, Hong L, Fang SQ, et al. Overexpression of pyruvate kinase M2 predicts a poor prognosis for patients with osteosarcoma[J]. Tumour Biol, 2016, 37(11):14923-14928.
doi: 10.1007/s13277-016-5401-7 URL |
| [40] | 赵晓莹. 联合检测血浆中PKM2和CEA在人结肠癌中的临床价值[J]. 中国现代药物应用, 2018, 12(12):31-32. |
| [41] |
Kumar Y, Gurusamy K, Pamecha V, et al. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis[J]. Pancreas, 2007, 35(2):114-119.
doi: 10.1097/mpa.0b013e3180537237 URL |
| [42] |
Liu W, Woolbright BL, Pirani K, et al. Tumor M2-PK: A novel urine marker of bladder cancer[J]. PLoS One, 2019, 14(6):e0218737.
doi: 10.1371/journal.pone.0218737 URL |
| [43] |
Hardt PD, Mazurek S, Toepler M, et al. Faecal tumour M2 pyruvate kinase: A new, sensitive screening tool for colorectal cancer[J]. Br J Cancer, 2004, 91(5):980-984.
doi: 10.1038/sj.bjc.6602033 URL |
| [44] | 蔡尚霞, 姜海英, 杨浩. 宫颈、阴道分泌物和血清PKM2检测在子宫内膜癌、宫颈癌诊断中的意义[J]. 中国实验诊断学, 2020, 24(4):622-623. |
| [45] | Guan M, Tong Y, Liu X, et al. Enzyme kinetic assay to measure the activity of tumor M2 pyruvate kinase in breast cancer patients[J]. Ann Clin Lab Sci, 2017, 47(6):676-686. |
| [46] |
Croner LJ, Dillon R, Kao A, et al. Discovery and validation of a colorectal cancer classifier in a new blood test with improved performance for high-risk subjects[J]. Clin Proteomics, 2017, 14:28.
doi: 10.1186/s12014-017-9163-z URL |
| [47] |
Wang D, Li C, Zhu Y, et al. TEPP-46-based AIE fluorescent probe for detection and bioimaging of PKM2 in living cells[J]. Anal Chem, 2021, 93(37):12682-12689.
doi: 10.1021/acs.analchem.1c02529 URL |
| [48] |
Beinat C, Haywood T, Chen YS, et al. The utility of [(18)F]DASA-23 for molecular imaging of prostate cancer with positron emission tomography[J]. Mol Imaging Biol, 2018, 20(6):1015-1024.
doi: 10.1007/s11307-018-1194-y URL |
| [49] |
Fung KY, Tabor B, Buckley MJ, et al. Blood-based protein biomarker panel for the detection of colorectal cancer[J]. Plos One, 2015, 10(3):e0120425.
doi: 10.1371/journal.pone.0120425 URL |
| [50] |
Kaura B, Bagga R, Patel FD. Evaluation of the pyruvate kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma[J]. J Obstet Gynaecol Res, 2004, 30(3):193-196.
doi: 10.1111/jog.2004.30.issue-3 URL |
| [51] | Landt S, Jeschke S, Koeninger A, et al. Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer[J]. Anticancer Res, 2010, 30(2):375-381. |
| [52] | 苏鹏, 陈海洋. 非小细胞肺癌患者血浆PKM2检测的临床意义[J]. 河北医药, 2017, 39(11):1623-1626. |
| [53] |
Parente F, Marino B, Ilardo A, et al. A combination of faecal tests for the detection of colon cancer: A new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study[J]. Eur J Gastroenterol Hepatol, 2012, 24(10):1145-1152.
doi: 10.1097/MEG.0b013e328355cc79 URL |
| [54] |
van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: A systematic review[J]. Eur Urol, 2005, 47(6):736-748.
pmid: 15925067 |
| [1] | Ye Qian, Ling Zhai, Liu Shenxiang, Lu Guotao, Yin Xudong. Meta analysis on effects of glucocorticoid on the immunotherapy of advanced cancer [J]. Clinical Focus, 2022, 37(7): 591-598. |
| [2] | LIU Bo-ru;WANG Ren-sheng. Spiral CT differential diagnosis of non thyroid-derived tumor in neck of elderly patients [J]. Clinical Focus, 2014, 29(8): 885-887. |
| [3] | ZHAO Jing-hui;ZHANG Lun;GU Feng;MA Yong-jie;FU Li;HAO Xi-shan. Influence of STAT3 expression on cisplatin sensitivity in head and neck squamous cell carcinoma [J]. CLINICAL FOCUS, 2009, 24(15): 1320-0. |
| [4] | . [J]. CLINICAL FOCUS, 2007, 22(22): 1605-1605. |
| [5] | . [J]. CLINICAL FOCUS, 2004, 19(16): 957-957. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||